TargetBeta
IRAK1
interleukin 1 receptor associated kinase 1 · also IRAK, pelle · Interleukin 1 receptor associated kinase family
2 programs in company-led studies act on IRAK1, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| pacritinibrule | Swedish Orphan Biovitrum | phase 3 | 183 running | ACVR1, FLT3, JAK2 | ChEMBL |
| ARD-885rule | Artivila (Shenzhen) Innovation Center | phase 1 | 10 running | IRAK4 | the studies' text |
Conditions their studies are in
- Arthritis, Rheumatoid, 1 program
- COVID-19, 1 program
- Hematologic Neoplasms, 1 program
- Hodgkin Disease, 1 program
- Leukemia, Myelomonocytic, Chronic, 1 program
- Primary Myelofibrosis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 30, 2026pacritinib · Swedish Orphan Biovitrum · phase 3 · NCT06782373
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.